Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.

Published

Journal Article

OBJECTIVE:The Brief Pain Inventory (BPI) was designed to yield separate scores for pain intensity and interference. It has been proposed that the pain interference factor can be further broken down into unique factors of affective (e.g., mood) and activity (e.g., work) interference. The purpose of this analysis was to confirm this affective/activity interference dichotomy. PATIENTS AND METHODS:A retrospective confirmatory factor analysis was completed for a sample of 184 individuals diagnosed with castrate-resistant prostate cancer (age 40-86, mean = 65.46, 77% White non-Hispanic) who had been administered the BPI as part of Cancer and Leukemia Group B trial 9480. A one-factor model was compared against two-factor and three-factor models that were developed based on the design of the instrument. RESULTS:Root mean squared error of approximation (0.075), comparative fit index (0.971), and change in chi-square, given the corresponding change in degrees of freedom (13.33, P < 0.05) values for the three-factor model (i.e., pain intensity, activity interference, and affective interference), were statistically superior in comparison with the one- and two-factor models. This three-factor structure was found to be invariant across age, mean prostate-specific antigen, and hemoglobin levels. CONCLUSIONS:These results confirm that the BPI can be used to quantify the degree to which pain separately interferes with affective and activity aspects of a patient's everyday life. These findings will provide clinical trialists, pharmaceutical sponsors, and regulators with confidence in the flexibility of the BPI as they consider the use of this instrument to assist with understanding the patient experience as it relates to treatment.

Full Text

Duke Authors

Cited Authors

  • Atkinson, TM; Halabi, S; Bennett, AV; Rogak, L; Sit, L; Li, Y; Kaplan, E; Basch, E; Cancer and Leukemia Group B,

Published Date

  • November 2012

Published In

Volume / Issue

  • 13 / 11

Start / End Page

  • 1417 - 1424

PubMed ID

  • 23110676

Pubmed Central ID

  • 23110676

Electronic International Standard Serial Number (EISSN)

  • 1526-4637

International Standard Serial Number (ISSN)

  • 1526-2375

Digital Object Identifier (DOI)

  • 10.1111/j.1526-4637.2012.01498.x

Language

  • eng